This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Axsome (AXSM) Up 15.2% Since Last Earnings Report?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome's (AXSM) Q3 Earnings In Line, Pipeline Progresses
by Zacks Equity Research
Axsome (AXSM) earnings meet estimates in the third quarter. The company stretches the timeline for the NDA filing for AXS-05 and AXS-07. Shares fall.
Axsome Expedites Development Plan for Narcolepsy Candidate
by Zacks Equity Research
Axsome (AXSM) accelerates the development plan for AXS-12 to treat narcolepsy after a Breakthrough Therapy meeting with the FDA authorities. Stock dips.
Axsome (AXSM) Down 10.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome's NDA Filing for Migraine Candidate in Q4 on Track
by Zacks Equity Research
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-07, which is developed as an acute treatment of migraine. The company is on course to file the NDA in Q4.
Axsome's (AXSM) Earnings Beat in Q2, Pipeline Progresses
by Zacks Equity Research
Axsome (AXSM) incurs a narrower loss in the second quarter of 2020. The company remains on track to submit the NDA for AXS-05 and AXS-07.
Axsome Focuses on Filling NDAs for Two CNS Candidates in 2020
by Zacks Equity Research
Axsome's (AXSM) CNS pipeline candidates are advancing well. NDAs for AXS-05 to address MDD and AXS-07 as an acute treatment of migraine will be filed in Q4. Lack of a marketed product is a concern.
Axsome's NDA for Depressive Disorder Drug on Track in Q420
by Zacks Equity Research
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA officials for AXS-05 to treat major depressive disorder. The company is on course to file the NDA in Q4.
Axsome's AXS-05 Gets Breakthrough Therapy Tag for AD Agitation
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy status on Axsome's (AXSM) AXS-05 for the treatment of Alzheimer's disease agitation. Shares rise.
Company News for Jun 29, 2020
by Zacks Equity Research
Companies in the news are: GPS, CLGX, AXSM, VXRT
Why Is Axsome (AXSM) Down 15.7% Since Last Earnings Report?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome's (AXSM) Earnings Miss in Q1, Pipeline Progresses
by Zacks Equity Research
Axsome (AXSM) incurs a wider loss in the first quarter of 2020. However, the company is advancing well with the NDA for AXS-05 and AXS-07.
Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study
by Zacks Equity Research
Axsome's (AXSM) AXS-07 achieves both regulatory co-primary endpoints in the phase III INTERCEPT study for the early treatment of migraine.
Axsome's (AXSM) AXS-05 Fails to Meet Main Goal in TRD Study
by Zacks Equity Research
Axsome's (AXSM) AXS-05 meets key secondary endpoints in late-stage study for addressing patients with treatment resistant depression. However, the primary endpoint did not reach statistical significance.
Axsome Expedites Completion Timeline of AD Study on AXS-05
by Zacks Equity Research
Axsome (AXSM) speeds up the evaluation time of AXS-05 under the phase II/III ADVANCE-1 study for Alzheimer's disease agitation to ensure safety of patients amid the COVID-19 pandemic.
Is the Options Market Predicting a Spike in Axsome Therapeutics (AXSM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.
What's in Store for Axsome (AXSM) This Earnings Season?
by Zacks Equity Research
On Axsome's (AXSM) fourth-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.
Axsome Therapeutics (AXSM) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Axsome Therapeutics (AXSM) closed at $87.60 in the latest trading session, marking a +0.72% move from the prior day.
Axsome (AXSM) Completes Patient Randomization in TRD Study
by Zacks Equity Research
Axsome (AXSM) closes patient randomization in the late-stage study of AXS-05 for addressing patients with treatment resistant depression.
ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why
by Zacks Equity Research
ACADIA's (ACAD) only marketed drug Nuplazid registers strong sales in 2019. The drug's label expansion efforts also look promising with several studies currently underway for various CNS disorders.
Do Options Traders Know Something About Axsome (AXSM) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Axsome (AXSM) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: Cirrus Logic, CIRCOR, Axsome and Digital Turbine
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cirrus Logic, CIRCOR, Axsome and Digital Turbine
Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study
by Zacks Equity Research
Axsome's (AXSM) migraine drug meets two regulatory, co-primary endpoints in a phase III study.
Top 2019 Wall Street Stories That May Hit Headlines in 2020
by Sweta Killa
We discuss some of the events that dominated the headlines in 2019 and influenced the market.
Biotech Rally Sends Nasdaq to 9000: ETFs in Focus
by Sanghamitra Saha
Some biotech stocks have contributed materially to the Nasdaq's 1000-point gain since Aug 27, 2018 and helped it notch a record 9,000 on Dec 26.